- Home
- IMNN vs CNVS Comparison
IMNN vs CNVS Comparison
Compare IMNN & CNVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- CNVS
- Stock Information
- Founded
- IMNN 1982
- CNVS 2000
- Country
- IMNN United States
- CNVS United States
- Employees
- IMNN N/A
- CNVS N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- CNVS Consumer Electronics/Video Chains
- Sector
- IMNN Health Care
- CNVS Consumer Discretionary
- Exchange
- IMNN Nasdaq
- CNVS Nasdaq
- Market Cap
- IMNN 12.1M
- CNVS N/A
- IPO Year
- IMNN 1985
- CNVS 2003
- Fundamental
- Price
- IMNN $0.77
- CNVS $6.04
- Analyst Decision
- IMNN Buy
- CNVS Buy
- Analyst Count
- IMNN 2
- CNVS 1
- Target Price
- IMNN $14.00
- CNVS $10.00
- AVG Volume (30 Days)
- IMNN 2.3M
- CNVS 373.4K
- Earning Date
- IMNN 08-13-2025
- CNVS 08-13-2025
- Dividend Yield
- IMNN N/A
- CNVS N/A
- EPS Growth
- IMNN N/A
- CNVS N/A
- EPS
- IMNN N/A
- CNVS 0.16
- Revenue
- IMNN N/A
- CNVS $78,181,000.00
- Revenue This Year
- IMNN N/A
- CNVS N/A
- Revenue Next Year
- IMNN N/A
- CNVS N/A
- P/E Ratio
- IMNN N/A
- CNVS $37.75
- Revenue Growth
- IMNN N/A
- CNVS 59.13
- 52 Week Low
- IMNN $0.37
- CNVS $0.72
- 52 Week High
- IMNN $3.65
- CNVS $6.24
- Technical
- Relative Strength Index (RSI)
- IMNN 40.86
- CNVS 89.80
- Support Level
- IMNN $0.70
- CNVS $3.72
- Resistance Level
- IMNN $0.86
- CNVS $5.31
- Average True Range (ATR)
- IMNN 0.10
- CNVS 0.36
- MACD
- IMNN -0.05
- CNVS 0.19
- Stochastic Oscillator
- IMNN 10.34
- CNVS 92.06
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).